Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Vyriad, Imanis Ink Cancer Companion Dx Development Deal

Vyriad, Imanis Ink Cancer Companion Dx Development Deal

Aug 16, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Vyriad announced today that it has partnered with Imanis Life Sciences to develop in vitro and in vivo tests to predict a patient's likelihood of responding to its oncolytic virus therapeutics.

Vyriad is developing cancer treatments that use vesicular stomatitis and measles viruses modified with genes encoding known tumor antigens in order to trigger anticancer immune responses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Swabs for Science of Spread

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

Genome of the Murder Hornet

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

In a Pool Together

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

Science Presents Paper on Computational Method to Predict IBD Patient Response to Therapy

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.

Aug
18
Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Sponsored by
Bio-Rad

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Aug
26
Featured Webinar

Resolving Complex Haplotypes Implicated in Alzheimer’s and Other Neurodegenerative Diseases

Sponsored by
Bionano Genomics

Alzheimer’s disease is genetically complex with no meaningful therapies or pre-symptomatic disease diagnostics. 

What's Popular?

In Molecular Diagnostics

  1. Guardant Health CDx Wins FDA Approval for First Liquid Biopsy NGS Tumor Profiling Assay

  2. Guardant Health Q2 Revenues Rise 23 Percent

  3. Natera Files Additional Patent Infringement Lawsuit Against ArcherDx

  4. Wide Variation in Genomic Testing Utilization Across US, Report Finds

  5. Luminex Responds to FDA Warning Letter While Ramping SARS-CoV-2 Test Manufacturing

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.